Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006348 · ClinicalTrials.gov registry record · Phase 3

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
100
Enrollment target

NCT00006348 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006348, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
100 participants
Enrollment target

Study Summary

RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

Interventions

  • OTHER placebo
  • DRUG ondansetron

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2000-10
Est. Completion 2001-09
Phase Phase 3

What the Registry Record Tells You About NCT00006348

The ClinicalTrials.gov registry entry for NCT00006348 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00006348 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00006348 about?

NCT00006348 is a clinical study titled "Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment". RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea an...

What is the current status of trial NCT00006348?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2000-10. Estimated completion is 2001-09.

What interventions are being tested in trial NCT00006348?

The interventions under investigation include: placebo (OTHER), ondansetron (DRUG).

Who is sponsoring clinical trial NCT00006348?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.